OBJECTIVE: To share our decades of experience with primary myelofibrosis and underscore the importance of outcomes research studies in designing clinical trials and interpreting their results. PATIENTS AND METHODS: One thousand consecutive patients with primary myelofibrosis seen at Mayo Clinic between November 4, 1977, and September 1, 2011, were considered. The International Prognostic Scoring System (IPSS), dynamic IPSS (DIPSS), and DIPSS-plus were applied for risk stratification. Separate analyses were included for patients seen at time of referral (N=1000), at initial diagnosis (N=340), and within or after 1 year of diagnosis (N=660). RESULTS: To date, 592 deaths and 68 leukemic transformations have been documented. Parameters at initial diagnosis vs time of referral included median age (66 vs 65 years), male sex (61% vs 62%), red cell transfusion need (24% vs 38%), hemoglobin level less than 10 g/dL (38% vs 54%), platelet count less than 100 × 10(9)/L (18% vs 26%), leukocyte count more than 25 × 10(9)/L (13% vs 16%), marked splenomegaly (21% vs 31%), constitutional symptoms (29% vs 34%), and abnormal karyotype (31% vs 41%). Mutational frequencies were 61% for JAK2V617F, 8% for MPLW515, and 4% for IDH1/2. DIPSS-plus risk distributions at time of referral were 10% low, 15% intermediate-1, 37% intermediate-2, and 37% high. The corresponding median survivals were 17.5, 7.8, 3.6, and 1.8 years vs 20.0, 14.3, 5.3, and 1.7 years for patients younger than 60 years of age. Compared with both DIPSS and IPSS, DIPSS-plus showed better discrimination among risk groups. Five-year leukemic transformation rates were 6% and 21% in low- and high-risk patients, respectively. CONCLUSION: The current document should serve as a valuable resource for patients and physicians and provides context for the design and interpretation of clinical trials.
OBJECTIVE: To share our decades of experience with primary myelofibrosis and underscore the importance of outcomes research studies in designing clinical trials and interpreting their results. PATIENTS AND METHODS: One thousand consecutive patients with primary myelofibrosis seen at Mayo Clinic between November 4, 1977, and September 1, 2011, were considered. The International Prognostic Scoring System (IPSS), dynamic IPSS (DIPSS), and DIPSS-plus were applied for risk stratification. Separate analyses were included for patients seen at time of referral (N=1000), at initial diagnosis (N=340), and within or after 1 year of diagnosis (N=660). RESULTS: To date, 592 deaths and 68 leukemic transformations have been documented. Parameters at initial diagnosis vs time of referral included median age (66 vs 65 years), male sex (61% vs 62%), red cell transfusion need (24% vs 38%), hemoglobin level less than 10 g/dL (38% vs 54%), platelet count less than 100 × 10(9)/L (18% vs 26%), leukocyte count more than 25 × 10(9)/L (13% vs 16%), marked splenomegaly (21% vs 31%), constitutional symptoms (29% vs 34%), and abnormal karyotype (31% vs 41%). Mutational frequencies were 61% for JAK2V617F, 8% for MPLW515, and 4% for IDH1/2. DIPSS-plus risk distributions at time of referral were 10% low, 15% intermediate-1, 37% intermediate-2, and 37% high. The corresponding median survivals were 17.5, 7.8, 3.6, and 1.8 years vs 20.0, 14.3, 5.3, and 1.7 years for patients younger than 60 years of age. Compared with both DIPSS and IPSS, DIPSS-plus showed better discrimination among risk groups. Five-year leukemic transformation rates were 6% and 21% in low- and high-risk patients, respectively. CONCLUSION: The current document should serve as a valuable resource for patients and physicians and provides context for the design and interpretation of clinical trials.
Authors: T L Lasho; C M Finke; C A Hanson; T Jimma; R A Knudson; R P Ketterling; A Pardanani; A Tefferi Journal: Leukemia Date: 2011-11-08 Impact factor: 11.528
Authors: P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett Journal: Blood Date: 1997-03-15 Impact factor: 22.113
Authors: C D Bloomfield; C Shuma; L Regal; P P Philip; D K Hossfeld; A M Hagemeijer; O M Garson; B A Peterson; M Sakurai; G Alimena; R Berger; J D Rowley; T Ruutu; F Mitelman; G W Dewald; J Swansbury Journal: Cancer Date: 1997-12-01 Impact factor: 6.860
Authors: K Stam; N Heisterkamp; G Grosveld; A de Klein; R S Verma; M Coleman; H Dosik; J Groffen Journal: N Engl J Med Date: 1985-12-05 Impact factor: 91.245
Authors: Haris Ali; Ibrahim Aldoss; Dongyun Yang; Sally Mokhtari; Samer Khaled; Ahmed Aribi; Michelle Afkhami; Monzr M Al Malki; Thai Cao; Matthew Mei; Margaret O'Donnell; Amandeep Salhotra; Vinod Pullarkat; Lixin Yang; Anthony S Stein; Guido Marcucci; Stephen J Forman; Ryotaro Nakamura; Raju Pillai; David Snyder Journal: Blood Adv Date: 2019-01-08
Authors: Tania Jain; Katie L Kunze; M'hamed Temkit; Daniel K Partain; Mrinal S Patnaik; James L Slack; Nandita Khera; William J Hogan; Vivek Roy; Pierre Noel; Jose F Leis; Lisa Z Sproat; Veena Fauble; Ruben A Mesa; Jeanne Palmer Journal: Bone Marrow Transplant Date: 2018-05-24 Impact factor: 5.483
Authors: A Tabarroki; D J Lindner; V Visconte; L Zhang; H J Rogers; Y Parker; H K Duong; A Lichtin; M E Kalaycio; M A Sekeres; S E Mountantonakis; G A Heresi; R V Tiu Journal: Leukemia Date: 2014-01-10 Impact factor: 11.528
Authors: Rami S Komrokji; John F Seymour; Andrew W Roberts; Martha Wadleigh; L Bik To; Robyn Scherber; Elyce Turba; Andrew Dorr; Joy Zhu; Lixia Wang; Tanya Granston; Mary S Campbell; Ruben A Mesa Journal: Blood Date: 2015-03-11 Impact factor: 22.113
Authors: Malte Asshoff; Verena Petzer; Matthew R Warr; David Haschka; Piotr Tymoszuk; Egon Demetz; Markus Seifert; Wilfried Posch; Manfred Nairz; Pat Maciejewski; Peter Fowles; Christopher J Burns; Gregg Smith; Kay-Uwe Wagner; Guenter Weiss; J Andrew Whitney; Igor Theurl Journal: Blood Date: 2017-02-10 Impact factor: 22.113
Authors: Hagop M Kantarjian; Richard T Silver; Rami S Komrokji; Ruben A Mesa; Roland Tacke; Claire N Harrison Journal: Clin Lymphoma Myeloma Leuk Date: 2013-10-02